IRLAB Therapeutics AB Class A (IRLAB.A) Stock Statistics & Valuation Metrics

IRLAB Therapeutics AB Class A has a market cap or net worth of kr153.91M. The enterprise value is kr73.44M.

IRLAB Therapeutics AB Class A has 84,858,246 shares outstanding. The number of shares has decreased by -2.65% in one year.

IRLAB Therapeutics AB Class A’s return on equity (ROE) is -2.55 and return on invested capital (ROIC) is -80.72%.

The current PE Ratio of IRLAB Therapeutics AB Class A is ―. IRLAB Therapeutics AB Class A’s PEG ratio is 0.13.

In the last 12 months, IRLAB Therapeutics AB Class A had revenue of 94.63M and earned -83.13M in profits. Earnings per share was -1.60.

In the last 12 months, operating cash flow was -53.65M and capital expenditures 0.00, giving a free cash flow of -53.65M billion.

IRLAB Therapeutics AB Class A pays an annual dividend of ―, resulting in a dividend yield of ―

IRLAB Therapeutics AB Class A upcoming earnings date is Feb 11, 2026, TBA (Confirmed).

IRLAB Therapeutics AB Class A as a current ratio of 0.80, with Debt / Equity ratio of 54.98%

In the past 12 months, IRLAB Therapeutics AB Class A has paid 0.00 in taxes.

IRLAB Therapeutics AB Class A EV to EBITDA ratio is -8.10, with an EV/FCF ratio of -8.38.

IRLAB Therapeutics AB Class A has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.

Gross margin is -38.98%, with operating margin of -79.38%, and net profit margin of -87.85%.

The average price target for IRLAB Therapeutics AB Class A is ―, which is 11.43% higher than the current price. The consensus rating is ―